65,437 trials
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 3 Participants
Breast Cancer
Primary: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. — 6.93; 2.83 months — p=<0.0001
Major Depressive Disorder
Primary: Percentage of Participants With Remission Based on Hamilton Depression Scale (HAM-D) — 54.4 Percentage of participants
Prostatic Neoplasms · Metastases, Neoplasm
Primary: Dose Limiting Toxicities (DLTs) — 0; 0; 2 Participants
Antimicrobial Effectiveness
Primary: Antimicrobial Efficacy — 2.21; 2.25 log 10 colony forming units / cm^2 — p=< 0.05
Jaw, Edentulous, Partially
Primary: Mean Change in Bone Level (Distance B) After 6 Months Compared to Baseline (=Surgery) — -0.32; -0.29 millimeters
Healthy Children After Vaccination
Primary: Percentage of Participants With Febrile Reactions Post-dose 1 — 14.3; 16.1; 1.8; 0.0 Percentage of participants
Obesity
Primary: Percent Weight Change at End of Treatment, Week 108. — -1.8; -9.32; -10.5 percent weight loss — p=<0.0001
HIV Infections
Primary: Proportion of Patients Reporting Adverse Events — 25.5; 4.3; 9.7; 3.2 Percentage of participants
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: Progression-free Survival at 6 Months — 23 Percentage of participants
Brain Edema · Brain Tumor
Primary: Long Term Safety and Tolerability of hCRF — 111 Participants
Rheumatoid Arthritis
Primary: Percentage of Patients Developing a Serious Adverse Event (SAE) Within 24 Weeks After Receiving the First Course of Rituximab Treatment — 6.0; 9.1 Percentage of…
Diabetes Mellitus Type 2 in Nonobese · Gastric Cancer
Primary: Morbidity — 4 participants
Hereditary Angioedema · Angioneurotic Edema
Primary: Time to Beginning of Relief of Symptoms — 68; 122; 258; 62.5 minutes — p=0.001
Bacterial Infection
Primary: Clinical Response at the Test of Cure (TOC) Visit in the Modified Intent-to-treat (MITT) Population — 84.7; 88.9 percentage of participants